Topic
Geoff Oxnard
1 recent story · updated continuously
Benzinga
BlossomHill Therapeutics to Showcase Promising Phase 1 Results of BH-30643 for Advanced EGFR-Mutant NSCLC at ASCO 2026
health
Just now
